Company news
Humacyte, Inc. (NASDAQ:HUMA) news
Humacyte, Inc. news releases on 6ix. Latest, Sep 28, 2026: Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Press releases & updates
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
September 28, 2026
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
September 9, 2026
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
August 24, 2026
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
August 19, 2026
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
August 18, 2026
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
August 7, 2026
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
July 27, 2026
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
July 14, 2026
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting
June 15, 2026
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
June 10, 2026
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
May 26, 2026
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
May 20, 2026
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
May 12, 2026
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
May 8, 2026
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
April 27, 2026
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®
April 24, 2026
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
April 21, 2026
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
April 21, 2026
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 27, 2026
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
March 25, 2026
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
March 23, 2026
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
March 19, 2026
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
March 18, 2026
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
March 16, 2026
Humacyte To Participate in Upcoming Investor Conferences
March 2, 2026
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 18, 2026
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
February 9, 2026
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
January 8, 2026
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
January 5, 2026
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
December 22, 2025
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
December 16, 2025
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
November 20, 2025
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
November 13, 2025
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
November 10, 2025
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
November 6, 2025
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
October 30, 2025
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
October 7, 2025
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
October 6, 2025
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
September 29, 2025
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
September 18, 2025
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
September 15, 2025
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
August 7, 2025
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
July 23, 2025
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
July 8, 2025
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
June 9, 2025